U-M researchers conducted first human trials of ketamine

Author | Lauren Talley

Close-up of a nurse's hands holding a syringe of ketamine that she is attaching to IV tubing
Photo by Leisa Thompson

Before it was studied as a treatment for depression and chronic pain, scientists developed ketamine as a safer alternative to an earlier anesthetic, PCP.

In the 1960s, chemists at Detroit-based pharmaceutical company Parke-Davis reached out to U-M to study ketamine.

In 1965, U-M pharmacology professor emeritus Edward F. Domino and anesthesiology professor Guenter Corssen published results of the first human trial of ketamine. The 20 subjects had good blood pressure, respiration rate, and other vital signs. And the risk of death was significantly lower compared to other general anesthetics available at the time.

Domino and Corssen also collaborated on the first clinical trial of ketamine. They published results in 1966 showing ketamine was a safe anesthetic in the 130 subjects undergoing surgery. Because of its short-acting pain-relieving properties, ketamine became a widely-used battlefield anesthetic in the Vietnam War.

The subjects of the 1965 study were people incarcerated at Jackson State Prison. The study was overseen by an ethics committee, and in 2017 Domino said, “To this day, NIH guidelines for prison research are based on what happened here.”

Sources:
Garber, Ken. “Listening to Ketamine: An anesthetic with Michigan roots is pulling people from the depths of depression.” Ann Arbor Observer, November 2022

Denomme, Nicholas. “The Domino Effect: Ed Domino’s early studies of Psychoactive Drugs.” Journal of Psychoactive Drugs, 50:4, 298-305,DOI: 10.1080/02791072.2018.1506599

Featured News & Stories doctor in white coat with dark blue scrubs touching hand of patient in grey sweater and baseball cap in exam room
Health Lab
Neuropathy common, and mostly undiagnosed, among patients in this Michigan city
A research team, led by Michigan Medicine and in partnership with Hurley Medical Center, finds that nearly three-quarters of patients at a clinic in Flint, Mich., a community that is predominantly Black and socioeconomically disadvantaged, had neuropathy — of which 75% was undiagnosed.
cancer cell blue yellow
Health Lab
Widening inequality seen where cancer clinical trials are available
The availability of clinical trials of new treatments for cancer varies greatly by geography, and a new study shows more socially vulnerable areas have far fewer.
man in black polo folded arms smiling no teeth bright orange background
Health Lab
Comedy and medicine
An ophthalmologist and beloved comedian shares his thoughts on the field to aspiring clinicians.
man smiling with cupcakes glasses
Health Lab
Two heart transplants, one message for organ donation
A patient who has received two heart transplants years apart shares his story and the importance of advocating for organ donation.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Cannabis and psychedelics: stigmatized substances or powerful therapeutics?
Today on The Fundamentals is Dr. Kevin Boehnke, research assistant professor in the Department of Anesthesiology and the Chronic Pain and Fatigue Research Center. His current research focuses on therapeutic applications of cannabis and psychedelics. His goal is to rigorously assess appropriate use of these substances and to help address the public health harms caused by their criminalization.
Health Lab
Mother-son heart bond: Woman relives congenital heart journey through newborn
A mother relives congenital heart journey through newborn.